J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
This article was originally published in The Tan Sheet
Quality control problems for Johnson & Johnson's McNeil Consumer Healthcare business and the regulatory and congressional scrutiny that followed dominated the attention of drug and dietary supplement industry stakeholders in 2010.
You may also be interested in...
Elections Reshape FDA Oversight Scene On Capitol Hill
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.
FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action
FDA will warn firms only once - if at all - before taking stronger enforcement actions to stop systematic quality and safety problems, said Howard Sklamberg, director of the Office of Enforcement at the Office of Regulatory Affairs
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.